Immunity and bacterial colonisation in bronchiectasis

Deborah Whitters, Robert Stockley

Queen Elizabeth Hospital, Lung Investigation and Sleep Department, Edgbaston, Birmingham, UK

Correspondence to

Dr Deborah Whitters, Queen Elizabeth Hospital, Lung Investigation and Sleep Department, Outpatient area 3, Mindelsohn Way, Edgbaston, Birmingham B15 2WB, UK; deborah.whitters@uhb.nhs.uk

Received 17 March 2011
Accepted 28 August 2011

Published Online First
20 September 2012

ABSTRACT

Background Non-cystic fibrosis bronchiectasis is characterised by irreversibly dilated bronchi usually associated with chronic sputum production, bacterial colonisation of the lower respiratory tract, inflammation and frequent exacerbations. Irrespective of the underlying cause, this represents failure of the host defence to maintain sterility of the respiratory tract.

Objective To review the interactions and associations of non-cystic fibrosis bronchiectasis with the innate and adaptive immune systems with particular emphasis on known failure of local defences established deficiencies of the adaptive immune system. In addition we wished to explore potential subtle changes in the host defence which can lead to bacterial colonisation together with bacterial factors that aid colonisation of the lower respiratory tract and impair antibiotic response. This latter concept is considered with particular reference to *Pseudomonas aeruginosa*, which is often found in the airway secretions of patients with non-cystic fibrosis bronchiectasis and may act as a model for other organisms.

Methods An extensive literature review was undertaken to provide a comprehensive review of immunity and bacterial colonisation in non-cystic fibrosis bronchiectasis, with focus on in vitro studies examining bacterial factors which may facilitate colonisation together with potential implications for management.

Conclusion These themes provide a review of the current understanding of non-cystic fibrosis bronchiectasis together with areas for future research and potential therapeutic strategies.

INTRODUCTION

Bronchiectasis is a pathological condition of lung damage characterised by inflamed dilated and thick-walled bronchi. It may be localised or diffuse, with the underlying cause identifiable in about 50% of cases.¹ Clinical features of bronchiectasis include chronic production of sputum often mucopurulent or purulent in nature, persistent bacterial colonisation and recurrent lower respiratory tract infections. Symptoms include haemoptysis (especially during exacerbations) and breathlessness characterised by mild to moderate airflow obstruction, lethargy and reduced health status.²

Underlying conditions associated with bronchiectasis are summarised in table 1.

Whatever the cause, patients with bronchiectasis are often colonised with bacterial species, even in the stable state. This indicates failure of the usual host defences that have evolved to maintain sterility of the respiratory tract. The purpose of the current article is to provide a review of bacterial and host factors in more classical idiopathic bronchiectasis in order to identify pathophysiological features that may explain the propensity for

bacterial colonisation.³ In particular, we wish to explore more subtle changes in host defence as well as bacterial factors that may facilitate colonisation and/or impair antibiotic response. These data may provide a more rational approach for the future management of the disease and provide insight into the problems of bacterial colonisation of the lower respiratory tract in general.

IMMUNE SYSTEM AND ITS INTERACTIONS/ ASSOCIATIONS WITH BRONCHIECTASIS

The concept of the 'vicious cycle' hypothesis of bronchiectasis implicates failure of host defence leading to a host-mediated chronic inflammatory response causing new or further impairment of mucociliary clearance and host defences, thereby amplifying the problem.⁴ The interplay between organisms and host defence represents a frustrated attempt at clearance, leading to excessive inflammation (in some), further impairment of host defences, and establishing and maintaining a vicious cycle.

Of particular interest in bronchiectasis are the bacteria which commonly colonise the lung and especially *Pseudomonas aeruginosa* (*P. aeruginosa*), which interacts with the host, and has immunomodulatory properties that facilitate its survival. These features of the immune system in bronchiectasis will be particularly explored below.

The overall interaction between lung host defences and bacteria is summarised in figure 1.

THE INNATE IMMUNE SYSTEM OF THE LUNG

The innate immune system is the immediate, non-specific and first line of defence against invading organisms. The mucociliary escalator is lined by ciliated and mucus-producing cells. Particles >2–3 µm impact on the mucus covering epithelial cells in the upper airways and bronchi and are removed by a combination of normal mucociliary clearance and cough.^{5–6} Airway secretions also contain several anti-infective proteins and polypeptides, including the bacteriostatic proteins lysozyme and lactoferrin. Secretory leucoprotease inhibitor (SLPI), produced by the mucous glands, macrophages and epithelial cells, has antifungal, antiviral and antibacterial properties.⁷ The role of antimicrobial proteins and peptides is discussed later together with neutrophils and their role in bronchiectasis. Lactoferrin, SLPI, lysozyme and defensins are (among others), derived from recruited neutrophils in addition to submucosal glands (for lactoferrin).⁷

Secretory IgA is the main antibody isotype in mucosal secretions in the respiratory tract that contributes to the initial defence mechanisms, while IgG predominates in the plasma.⁸ Most lung IgA is produced locally within the pulmonary

Table 1 Causes of bronchiectasis

Post infective	Viral (adenovirus, measles, HIV) Bacterial (pneumococcus) Mycobacterium tuberculosis Whooping cough
Host Immune defects	Allergic Bronchopulmonary aspergillosis Humoral immune deficiency (IgA, IgG, IgM) Selective IgG subclass deficiency Specific antibody deficiency Complement deficiency Chronic granulomatous disease
Mucociliary clearance defects	Primary ciliary dyskinesia Kartageners syndrome Youngs syndrome
Other inflammatory disease	Rheumatoid arthritis Inflammatory bowel disease Chronic obstructive pulmonary disease
Others	Foreign body inhalation Middle lobe syndrome α -1-Antitrypsin deficiency Toxic inhalation Gastro-oesophageal reflux disease Yellow nail syndrome

tissues by subepithelial plasma cells. Postmortem studies of lung tissue indicate an increased number of IgA-positive cells in bronchitic and bronchiectatic lungs compared with controls.⁹

The proportion of the IgA subclasses is different in lung secretions and blood. Most of the blood IgA is of the IgA1 subclass with 10–20% being IgA2, whereas lung secretions have around 30% IgA2. Stability of IgA2 is maintained better than IgA1 in the presence of infection because of resistance to IgA proteases produced by many pathogenic bacteria.⁹ There is increased production of IgA2 in the presence of infection indicated by an increase in the proportion of IgA2 with increasing sputum purulence.¹⁰ IgA in airway secretions binds to lectin-like bacterial adhesins blocking epithelial colonisation and operating as a generic immune barrier. In addition, IgA promotes phagocytosis by binding to Fc receptors expressed on the surface of eosinophils, neutrophils and monocytes.⁹ IgA enables delivery of antigens across the epithelium into luminal secretions, thereby removing locally formed immune complexes and limiting access to the systemic circulation. Mucosal IgA production is maintained by factors such as interleukin (IL)-2, IL-5, IL-6 and IL-10 generated by airway epithelial cells.⁹

If these primary clearance mechanisms are overwhelmed by a high bacterial load, a secondary defence system is activated. Animal experiments clearly demonstrate this relationship between bacterial load and activation of the secondary host response in that a low bacterial load leads to bacterial clearance, but when the bacterial load is greater than 10^6 colony-forming units/ml (cfu/ml) there is a neutrophilic host inflammatory response.¹¹

Failure of the local host defences results in microbial colonisation, establishing the 'vicious cycle' described above. Airway epithelium responds by releasing antimicrobial peptides and inflammatory cytokines into the airways. In human airway epithelial cells the main classes of antimicrobial peptides produced are the β -defensins and the cathelicidins (IL-37 in humans). Chemokines and cytokines such as IL-8 are released into the submucosa¹² and initiate the inflammatory reaction, leading to recruitment of phagocytes (neutrophils, monocytes and macrophages), dendritic cells and lymphocytes, which contribute to the adaptive response.¹³ The airways become

Figure 1 Interactions between lung host defence and bacteria. This diagram demonstrates the breach in the lung defence precipitated either by a genetic predisposition, infection or abnormal primary host immune defence (innate immune system). The initial breach (1) leads to further impairment of the host defence with impaired bacterial clearance (2). Impaired bacterial clearance can also be initiated by a decreased or abnormal secondary host immune response (adaptive immune system) (3) with failure of the system to respond to an insult with a 'learned' response. The normal secondary response can also be impaired by further damage. This impairment of bacterial clearance leads to a state of bacterial colonisation and ongoing and increased inflammation as a result of continuing release of anti-defence proteins. As previously described by Cole *et al*⁴ the vicious cycle is set in motion and a state of continuing infection and inflammation (4) exists with progressive lung damage. A normal and intact secondary response (5) ought to prevent bacterial colonisation and further damage.

inflamed leading to leakage of serum proteins including circulating antibodies and complement, therefore increasing local antibacterial potential.

ROLE OF NEUTROPHILS AND NEUTROPHILIC INFLAMMATION IN BRONCHIECTASIS

Neutrophil-dominant inflammation is a prominent feature in bronchiectasis. Neutrophils aggregate rapidly at the site of infection with three key actions. Namely, phagocytosis, the release of the contents of pre formed granules, and production of reactive oxygen species (ROS), all of which are directed at bacterial killing.^{14 15}

The internalisation of particles or bacteria and the formation of a phagosome are facilitated by opsonisation, which is when IgG antibodies bind to organisms by the Fab portion, with the Fc portion then binding to the phagocyte via specific receptors. Complement system proteins are activated either through Ig binding (classical pathway) or independently (alternative pathway), emphasising the importance of immunoglobulin and complement deficiency in the pathophysiology of bronchiectasis. Low or deficient serum Mannose-binding lectin activating

protein of the lectin pathway of the complement system has also been associated with bronchiectasis.^{16 17}

Normally the neutrophil moves to the site of phagocytosis in response to chemotactic stimuli. In bronchiectasis, leukotriene B₄ and IL-8 in addition to other chemotactic factors have been implicated, with IL-8 playing a more crucial role during acute exacerbations.¹⁸

Additionally, the granule proteins, formed during neutrophil development, and released on activation, have a vital role in neutrophil response.¹⁹ The three subsets of granules contain a variety of enzymes and host defence proteins with receptors, signalling proteins and adhesion molecules that become expressed on their membrane following activation. Through a hierarchical process of degranulation, azurophilic granules (primary granules) release (among others) myeloperoxidase, bactericidal/permeability-increasing protein, defensins, neutrophil elastase, proteinase 3 and cathepsin G. Specific granules (secondary granules) release other key antibacterial proteins such as lactoferrin and cathelicidin and tertiary (gelatinase) granules contain, and release, gelatinase acetyltransferase and lysozyme. The excessive degranulation and activity of cytolytic enzymes such as myeloperoxidase and elastase have been implicated most in host tissue damage.²⁰

The respiratory burst results in the release of ROS to facilitate bacterial killing. The release of uncontrolled ROS by neutrophils may however also lead to damage to surrounding tissues, amplifying the lung disease process.²¹ It had previously been thought that ROS exert a direct toxic effect on ingested pathogens. However Reeves *et al*²² suggested that the respiratory burst sets in motion events which result in creating a favourable environment for proteases such as elastase to digest the contents within the phagocytic vacuole. By optimising conditions via ion flux and pH change, the enzymes released from the cytoplasmic granules become more active, facilitating the destruction of ingested pathogens.

The respiratory burst is based upon the assembly and activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.²¹ The genetic defect of chronic granulomatous disease emphasises the importance of this pathway. It is caused by a defective gene for one of the subunits of NADPH oxidase and leads to an inability to produce ROS, resulting in recurrent life-threatening bacterial infections and granuloma formation.²³ Patients with this condition frequently develop a variety of inflammatory complications consistent with exaggerated inflammatory responses including bronchiectasis.²⁴

In 2006, King *et al*²⁵ demonstrated that phagocytosis was normal in patients with bronchiectasis compared with controls, but that oxidative burst was lower. It was suggested this was either due to a suppressive effect of bacterial products on neutrophil function or an intrinsic defect of neutrophil oxidative burst. However, earlier work by Pasteur *et al*¹ failed to demonstrate any significant difference in neutrophil respiratory burst. It remains possible that this represents an important abnormality but that its frequency depends on patient referral patterns. The basic physiological defect has yet to be identified.

TOLL-LIKE RECEPTORS

Toll-like receptors (TLRs) are a family of cell surface immune-modulatory proteins playing a crucial role in both the innate and adaptive immune response. They induce an immune response to a number of pathogenic factors with 10 human TLRs identified to date. These receptors play a vital role in recognising pathogens and their products, and thereafter activating the immune response.

TLRs recognise bacterial structures called pathogen-associated molecular patterns (PAMPs)²⁶ and TLR2, TLR4, TLR5, TLR6 and TLR9 have been specifically implicated in the recognition of bacterial components. TLR2 is expressed in human alveolar epithelial type II cells and alveolar macrophages,²⁷ and recognises peptidoglycan and lipoprotein, playing a role in mediating the inflammatory response to Gram-positive and mycobacterial products.²⁸ TLR4 is outer membrane associated and responsible for the recognition of lipopolysaccharide (LPS). TLR9 is found on the surface of endosomes and responds to nucleic-acid-based PAMPs of bacteria and viruses, whereas TLR5 is an outer membrane receptor for bacterial flagellin.^{29 30} Table 2 summarises the TLRs and the pathogens they respond to via PAMPs.

The interaction between the TLRs and PAMPs leads to activation of the innate host defence, especially the release of proinflammatory cytokines as demonstrated by lack of response in TLR knockout mice.³² In health, the interaction of PAMPs and TLRs is necessary for an appropriate host response to the specific pathogen.

This process has been clearly demonstrated for *P aeruginosa* and its interaction with TLRs, which is of particular importance in bronchiectasis given the morbidity associated with colonisation by this organism.³³ *P aeruginosa* is an opportunistic Gram-negative organism which is a recognised colonising organism in both idiopathic bronchiectasis and cystic fibrosis (CF), often in more severe bronchiectasis.^{34 35} Chronic colonisation with *P aeruginosa* has also been identified as an independent risk factor for an accelerated rate of decline in lung function.³³

P aeruginosa LPS is recognised by TLR4³² and induces lung inflammation in vivo.³⁶ In addition, TLR5 recognises flagellin expressed by *Pseudomonas*, with signalling assistance from TLR2,³⁷ leading to proinflammatory cytokine and chemokine production resulting in accumulation of neutrophils in the air spaces.³⁶

Skerrett *et al*³⁶ demonstrated (in mice) that TLR4 and flagellin-induced signals mediated most of the immune response to *Pseudomonas* and that TLR2 had a counter-regulatory role. They demonstrated a diminished tumour necrosis factor (TNF)- α response to *P aeruginosa* in bone marrow cells lacking TLR4 alone or with TLR2. Their studies have supported both specific and complementary roles for TLR2, TLR4 and TLR5 in the recognition of *P aeruginosa* and shown that signalling via these receptors accounts for most of the early cytokine and inflammatory response to infection.

Moreover, TLR5 surface expression has been shown to be upregulated on respiratory epithelial cells following exposure to *P aeruginosa* flagella.³⁷ TLR5 is stored intracellularly in neutrophils but activation of TLR1 and TLR2 mobilises the receptors to the cell surface. It has been proposed that TLR5 plays a vital role in the interactions between *P aeruginosa* and neutrophils in CF. Koller *et al*³⁸ confirmed this by demonstrating that activation of TLR5 by flagellin enhanced the production of IL-8, phagocytosis and respiratory burst by neutrophils. TLR4-deficient mouse models show a delay in clearance of *Haemophilus influenza*, which also colonises patients with bronchiectasis, following

Table 2 Toll-like receptors (TLRs) and their pathogens³¹

TLR1, 2, 6	Gram-positive bacteria
TLR3	Virus
TLR4	Gram-negative bacteria
TLR5	Bacteria, flagellum
TLR7, 8	Virus
TLR9	Bacteria, DNA

intrapulmonary administration with a diminished inflammatory response, suggesting a crucial role for this receptor in mediating an infective immune response to *H influenzae*.³⁹ The role of oligosaccharides from non-typeable *H influenzae* remains to be determined.

The role of TLRs in airway neutrophilic inflammation has been assessed in patients with asthma and bronchiectasis. In patients with neutrophilic asthma there was increased expression of TLR2 and TLR4 compared with controls and patients with eosinophilic and paucigranulocytic asthma. In patients with bronchiectasis, increased TLR2 mRNA was found in induced sputum but there was no difference in the expression of TLR4. It was suggested that the data may indicate differential expression of TLRs in bronchiectasis.⁴⁰ Whether this represents cause or effect remains to be determined.

Animal models of emphysema have also demonstrated increased expression of TLR2 and TLR4 in airway macrophages.⁴¹ It was proposed that this increased expression may enhance the immediate inflammatory response following inoculation with *Streptococcus pneumoniae*. Whether this is relevant to bronchiectasis also remains to be determined, but again *S pneumoniae* is often identified as a colonising organism.

ACQUIRED IMMUNE SYSTEM

The adaptive immune response is required to protect the lung against organisms that evade phagocytosis by macrophages leading to local replication.⁴² Marked defects of the adaptive immune response are adequately described elsewhere and thus only mentioned here briefly.

Primary antibody deficiency syndromes (PADS), all of which have been associated with bronchiectasis, involve partial or complete absence of one or more immunoglobulin class or subclass. In addition, there may be more subtle defects of specific responsive antibody formation,⁴³ as summarised in table 3.

The effect of common variable immune deficiency (CVID) is an inability to mount an appropriate and competent antibody response to pathogen epitopes. Kainulainen *et al*⁴⁴ found that bronchiectasis was present in 16 of 22 (73%) patients with either CVID or x-linked agammaglobulinaemia, with pathological progression in five patients over 3 years despite adequate immunoglobulin replacement therapy. Quinti *et al*⁴⁵ also demonstrated similar findings in 2007.

Evidence from patient series demonstrate overall increased survival in patients treated with immunoglobulin replacement. A number of patient series have also demonstrated reductions in acute and chronic infections in treated patients with PADS.^{46–47}

THE SIGNIFICANCE OF IGG SUBCLASS DEFICIENCIES IN BRONCHIECTASIS

IgG has four subclasses, each with different antibody responses. Low levels of isolated IgG subclasses have been identified, with undetectable levels of serum IgG4 present in up to 10% of healthy adults.⁴⁸

Hill *et al* concluded in 1998 that IgG subclass deficiency was comparatively rare in patients with bronchiectasis compared with age-matched healthy controls.⁴⁹ Similarly, King *et al*²⁵ showed no major abnormalities in testing of immunoglobulin levels in their cohort. Stead *et al*⁵⁰ also concluded that isolated antibody subclass deficiency was an uncommon cause or association with bronchiectasis in patients beyond the fourth decade.

More recently, Pasteur *et al*¹ found humoral immunodeficiency in 12 of 150 patients (8%), six of whom had isolated IgG deficiency. One patient was classified as having severe IgG2 deficiency with evidence of defective antibody production, and three had borderline low levels with evidence of defective antibody production alone. A further six patients had normal immunoglobulin levels but also evidence of isolated defective antibody production in response to antigen. The authors concluded that the relevance of isolated IgG subclass deficiency was not clear and that in addition to immunoglobulin and IgG subclass measurements, the need for functional studies was critical to investigate humoral immunity.

Similarly, Vendrell *et al*⁵¹ supported this finding in patients with idiopathic bronchiectasis and normal IgG levels and concluded antibody deficiency with normal IgG levels may be associated with bronchiectasis. They advised evaluation of antibody response to both *H influenzae* (capsular antigen) and pneumococcal (protein antigen) vaccines.

The role of immunoglobulin therapy is clearest in patients with CVID or agammaglobulinaemia aiming to reduce acute and chronic infections and their sequelae. However, immunoglobulin replacement in patients with specific antibody deficiency or subclass deficiency is less clear. Immunoglobulin replacement is less likely to be useful in partial subclass deficiencies or IgA deficiency without associated defects⁵² and indeed may be detrimental. Patients may become positive for IgG anti IgA antibodies, after exposure to IgA in blood products, and develop a predisposition for anaphylactoid reactions to intravenous immunoglobulin.⁵³

BLOCKING ANTIBODIES

Bactericidal blocking activity was described in the serum of patients with chronic Gram-negative infections by Waisbren and Brown in 1966, who suggested that the blocking factor may be an antibody.⁵⁴ Subsequent work in the 1970s demonstrated the bacterial blocking activity in chronic *P aeruginosa* infection in CF was IgG mediated.⁵⁵ Hornick and Fick⁵⁶ explored this concept of 'blocking antibodies' further and demonstrated that the IgG subclass response to *P aeruginosa* LPS was largely restricted to subclass 2. Further, they identified IgG2-containing immune complexes which inhibited bacterial phagocytosis by pulmonary macrophages and neutrophils. They also demonstrated an inhibitory effect of IgG2 immune complexes in the sera of patients with CF and chronic *P aeruginosa* colonisation. The authors concluded that sera from these patients functioned

Table 3 Primary antibody deficiency syndromes

Primary antibody deficiency	Immunoglobulin levels
Common variable immune deficiency	Low IgG, low IgA, $\pm$ low IgM with a failure to mount a significant antibody response to vaccination. ⁴⁴ Usually identified in first 24 months of life
X-linked agammaglobulinaemia	Low IgG, low IgA, low IgM. Often occurs in boys before the age of 2
IgG Subclass deficiencies	Low IgG subgroup 1–4
Specific antibody deficiency	Normal serum levels of immunoglobulin but failure to respond to test immunisation
Selective IgA deficiency	Often symptom free. Estimated to affect 1:700 population ⁴⁵

poorly as an opsonin and that IgG2 antibodies exert an anti-phagocytic effect both by direct inhibition and the formation of immune complexes.⁵⁶ This concept is summarised in figure 2.

Later work by Thomassen and Demko⁵⁷ demonstrated that patients with CF, in poor clinical condition, were more likely to have *Pseudomonas* strains that were resistant to serum bactericidal activity in autologous serum than those in a better clinical state. These strains were however sensitive to normal healthy serum, suggesting the presence of blocking activity in the serum. It was hypothesised that the development of this resistance was a contributory factor in the failure of the host to control infection leading to a poorer clinical condition.⁵⁷

More recently, the concept of blocking antibodies has been explored in detail in *Salmonella* infection in patients who are HIV positive. There is a high mortality associated with non-typhoidal strains of *Salmonella* in this patient group.⁵⁸ The data demonstrated a lack of bactericidal activity as a result of dysregulated humoral immunity in the sera, with excess IgG directed against *S typhimurium* LPS. By extracting LPS IgG from inhibitory HIV-infected serum and adding this to HIV-uninfected serum, the anti-LPS IgG was confirmed as the inhibitor of *S typhimurium* killing. Further studies by the same authors demonstrated that this inhibition could be overcome by adding IgG from HIV-uninfected sera to inhibitory HIV-infected sera in appropriate proportions. These data clearly demonstrated the importance of competing blocking and killing antibodies in

Figure 2 IgG2 and IgG2 containing immune complexes in the serum of patients with cystic fibrosis colonised with *Pseudomonas aeruginosa*. IgG2 has blocking activity by direct inhibition and the formation of IgG2-containing immune complexes in the serum of patients with cystic fibrosis and chronic *P aeruginosa* colonisation. Patients with cystic fibrosis and chronic *P aeruginosa* colonisation were found to have significantly elevated levels of IgG2. Phagocytosis by pulmonary macrophages is inhibited in the presence of serum from these patients while IgG2-containing immune complexes inhibit phagocytosis by pulmonary macrophages and neutrophils. It was concluded that sera from these patients does not function well as an opsonin. Patients with cystic fibrosis and chronic *P aeruginosa* colonisation also have elevated levels of these immune complexes. Removal of the immune complexes leads to a simultaneous fall in the levels of IgG2 and increased bacterial uptake by neutrophils and pulmonary macrophages. It is hypothesised that this may be due to competition by these immune complexes with opsonised bacteria for the Fc receptor sites on phagocytic cells. IC, immune complex.

patients infected with *Salmonella*, although the subclass was not identified.⁵⁸ Whether this plays a role in bronchiectasis remains to be investigated. However, of importance, antibodies to polysaccharides are usually of the IgG2 subclass, providing a potential link between the role of IgG2 in CF and the clinical effect of endotoxin-specific antibodies in *Salmonella* infection. Clearly further studies in both CF and non-CF bronchiectasis are indicated. In particular, the role of bactericidal blocking activity directed against *P aeruginosa* in these patients may provide some explanation for the propensity to chronic colonisation.

QUORUM SENSING AND BIOFILM DEVELOPMENT

A number of specific bacterial factors enhance the ability of the pathogen to evade host defences. These include adherence, the ability to impair ciliary clearance and damage the epithelial surface (which enhances both), and avoidance of phagocytosis.⁵⁶ Therefore, the balance between the innate and adaptive immune response and bacterial factors that avoid or subvert this response will result in either reduced bacterial clearance or facilitate proliferation leading to colonisation.

An area of increasing interest and research in bacterial behaviour is quorum sensing. This complex cell-to-cell signalling mechanism of bacterial populations modulates their behaviour and ability to survive, colonise and potentially invade the host. Quorum sensing is defined as the capacity to detect extracellular, small-molecule signals and to alter gene expression in response to bacterial population densities that reach a threshold concentration. These signalling pathways modulate various functions of the bacteria, including their metabolism, expression of virulence factors and biofilm formation.⁵⁹

Many common bacteria contain quorum-sensing genes. Much of the research to date has specifically examined the quorum-sensing system employed by *P aeruginosa*. It is difficult to eradicate and therefore its behaviours mediated by quorum-sensing systems and potential interactions with the host defence are likely to be of major importance.

The quorum sensing of Gram-negative bacteria is predominantly via the well characterised N-acyl homoserine lactone (AHL) signalling system.^{60 61} The AHL-based circuits are encoded by two signalling systems operating with specific signalling molecules, termed the Las and Rhl system. The two systems operate with specific signal molecules: 3-oxo C12-HSL for the lasR-encoded receptor and C4-HSL for the rhlR-encoded receptor.^{60 61} These systems also interact with host defences. Telford *et al*⁶² demonstrated that the *Pseudomonas* quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL) had immunomodulatory activity in addition to its recognised role in regulating virulence. Ritchie *et al*⁶³ showed direct effects on T cells and a role of this molecule in the initial stages of T-cell activation and Smith *et al*⁶⁴ demonstrated (in mice) that the quorum-sensing systems of *Pseudomonas* could induce inflammatory mediators in vivo via T cells, promoting the production of the inflammatory cytokine γ interferon.

In addition, 3-oxo-c12-HSL induces apoptosis in the neutrophils and macrophages. Tateda *et al*⁶⁵ proposed a mechanism of chronic *Pseudomonas* infection in the lungs involving quorum sensing whereby the formation of biofilms created a favourable environment for *Pseudomonas* survival. They suggested that 3-oxo-C12-HSL induced the production of neutrophil chemotactic factors (IL-8 in humans and macrophage inflammatory protein-2 in mouse models). This sets in motion a chain of events leading to tissue destruction and accelerated neutrophil

apoptosis, all of which contribute to the persistence of *Pseudomonas* in the lungs. In the presence of 3-oxo-C12-HSL neutrophil apoptosis is accelerated, therefore reducing bacterial killing capacity by these cells. Incubating neutrophils with 3-oxo-C12-HSL was shown to increase markers of apoptosis. It was proposed that apoptotic neutrophils also provide nutrients for the bacteria, facilitating their proliferation. This concept is outlined in figure 3. It is not known whether these *Pseudomonas* products are active in the airways of colonised patients with bronchiectasis and further studies are clearly needed to establish whether this process is important in establishing and maintaining colonisation of *P aeruginosa*.

One of the other important features of *P aeruginosa* is its ability to form biofilms. These are defined as a sessile community characterised by cells that are irreversibly attached to a surface or interface, or to each other, and embedded in a matrix of extracellular polymeric substance exhibiting an altered phenotype with respect to growth rate and gene transcription compared with planktonic bacteria.⁶⁶ Biofilms protect the bacterial population against host defence and increase the tolerance to antimicrobials. This is emphasised by their ability to form in the lungs of chronically ill patients, on catheters and on prosthetic valves, often requiring prolonged periods of antibiotic therapy to eradicate the organism.^{66 67} Links between biofilm formation and quorum sensing have been well established,^{60 67} although there are a number of other physical, biological and chemical factors involved in biofilm development. For example, when biofilms form on biomedical devices the process

begins with the coating of the device by proteins and glycoproteins, which may act as binding ligands.⁶⁸ Furthermore, in vivo, manipulation of the medium in which *P aeruginosa* is grown has been shown to influence the motility of bacterial populations and therefore the ability to form biofilms or the type of biofilm formed. *P aeruginosa* has been shown to form mushroom-like structures in flow cell reactors⁶⁹ However, in environments depleted of iron, flat biofilms are formed with wild-type *P aeruginosa*, which had previously grown in the classical mushroom form in an iron replete medium.⁷⁰ The primary source of carbon as a nutrient also influences the structure of the biofilm, which differs from those in which glucose is the main source rather than citrate. This is thought to be due to differences in the motility of the bacterial population influenced by the primary carbon source.⁷¹ By manipulating the quorum sensing of *P aeruginosa* populations and thereby creating las I mutants, the type and shape of biofilm formed is also influenced, with mutants forming flat biofilms compared with wild type.⁷² Subsequent work has suggested that the formation of biofilm, and its structure, is not solely dependent on quorum sensing but also on the medium in which the biofilm is cultivated.⁷³ Biofilm formation therefore represents a highly complex and multifactorial process, which is summarised in figure 4.

The components of the adaptive immune system and how they interact with biofilms and quorum sensing signalling molecules is, at least, partly understood. In 2005 Walker *et al*⁷⁴ demonstrated enhancement of biofilm development by neutrophils. However, the exact role of quorum sensing in biofilm formation in idiopathic bronchiectasis is less clear than in CF.⁷⁵ It should be noted that the *P aeruginosa* species of CF is usually of the mucoid phenotype. Whether the same processes are active in non-CF bronchiectasis, for which most of the *P aeruginosa* colonisation is non mucoid, remains to be determined. However, because *P aeruginosa* is a common colonising organism in both conditions and particularly in view of the difficulty in achieving microbial sterilisation in both, the data suggest that biofilm formation may also provide a protective bacterial mechanism in non-CF bronchiectasis.

Figure 3 Proposed interactions of quorum sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone (3-Oxo-C12-HSL) and the host defence. 3-Oxo-C12-HSL (1) is proposed to have immunomodulatory activities via T cells and promotes the production of inflammatory cytokines (γ interferon) and neutrophil chemotactic factors (interleukin-8 (IL8)/macrophage inflammatory protein-2 (MIP2)) (2) in addition to its recognised role in quorum sensing. Specifically it has been suggested that the production of these neutrophil chemotactic factors leads to accelerated neutrophil apoptosis (3). This, in turn, leads to persistence of *pseudomonas* by reduced killing by neutrophils due to early cell death, and it is proposed, the products of apoptosis provide nutrients for the bacteria, allowing its proliferation (4) and biofilm formation (5), protecting the bacteria further from phagocytes and antibiotics.⁶⁵

Figure 4 *P aeruginosa* biofilm life cycle. Stage 1: reversible attachment—individual bacterial cells populate the surface. Stage 2: irreversible attachment—extracellular polymeric substance is produced and attachment becomes irreversible. Stages 3–4: maturation phase—biofilm architecture develops and matures. Stage 5: dispersal—single cells are released from the biofilm and perpetuate the cycle. (Image reproduced with the permission of Peg Dirckx, Center for Biofilm Engineering, Montana State University, Bozeman, Montana, USA. ©MSU-CBE, P, Dirckx.)

Overall it is likely that quorum sensing and biofilm formation play a role in the ability of bacteria, and in particular *Paeruginosa*, to colonise the host but also contribute to its ability to persist in the lungs and subvert the host immune defence. The net result is excessive but ineffectual adaptive immunity which in itself may lead to perpetuation of bacterial colonisation, and continued neutrophil proteolytic and oxidative damage; that is the vicious cycle. Understanding these processes will be essential to the development of future effective therapeutic strategies, targeting their role in maintaining the vicious cycle.

CONCLUSION

In conclusion, it is clear that all aspects of the immune system and their perturbation by bacteria and their products are complex and central to the development, clinical presentation and management of bronchiectasis. Growing fields of interest and research include the roles of TLRs, blocking antibodies, quorum sensing and biofilms. Much of our knowledge so far has been obtained from animal models and infections outside of the lung, and the time has come to investigate the role of these factors in patients with bronchiectasis. The information obtained will be central to the future management of patients.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. *Am J Respir Crit Care Med* 2000;**162**:1277–84.
- Martinez-Garcia MA, Perpiná-Tordera M, Román-Sánchez P, et al. Quality of life determinants in patients with clinically stable bronchiectasis. *Chest* 2005;**128**:739–45.
- Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2004;**170**:400–7.
- Cole P, Wilson R. Host–microbial interrelationships in respiratory infection. *Chest* 1989;**95**:217S–21S.
- Nicod LP. Pulmonary defence mechanisms. *Respiration* 1999;**66**:2–11.
- Loebinger MR, Bilton D, Wilson R. Upper airway 2: bronchiectasis, cystic fibrosis and sinusitis. *Thorax* 2009;**64**:1096–101.
- Rogan MP, Geraghty P, Green CM, et al. Antimicrobial proteins and polypeptides in pulmonary innate defence. *Respir Res* 2006;**7**:29.
- Pilette C, Detry B, Guisette A, et al. Dual effect of neutrophils on secretory component production by human bronchial epithelial cells. *Eur Resp Rev* 2006;**15**:175–6.
- Burnett D, Crocker J, Stockley RA. Cells containing IgA subclasses in bronchi of subjects with and without chronic obstructive pulmonary disease. *J Clin Path* 1987;**40**:1217–20.
- Burnett D, Hill SL, Bradwell AR. IgA subclasses in sputum from patients with bronchiectasis. *Respir Med* 1990;**84**:123–7.
- Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. *Am J Med* 2000;**109**:288–95.
- Hiemstra PS. Antimicrobial peptides in the real world: implications for cystic fibrosis. *Eur Respir J* 2007;**29**:617–18.
- Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. *Eur Respir J* 2004;**23**:327–33.
- Cowburn AS, Condliffe AM, Farahi N, et al. Advances in neutrophil biology: clinical implications. *Chest* 2008;**134**:606–12.
- Stockley RA. Neutrophils and the pathogenesis of COPD. *Chest* 2002;**121**:151S–5S.
- Litzman J, Freiburger T, Grimbacher B, et al. Mannose-binding lectin gene polymorphic variants predispose to the development of bronchopulmonary complications but have no influence on other clinical and laboratory symptoms or signs of common variable immunodeficiency. *Clin Exp Immunol* 2008;**153**:324–30.
- Fevang B, Mollnes TE, Holm AM, et al. Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. *Clin Exp Immunol* 2005;**142**:576–84.
- Mikami M, Llewellyn-Jones CG, Bayley D, et al. The chemotactic activity of sputum from patients with bronchiectasis. *Am J Respir Crit Care Med* 1998;**157**:723–8.
- Borregaard N, Theilgaard-Mönch K, Sørensen OE, et al. Regulation of human neutrophil granule protein expression. *Curr Opin Hematol* 2001;**8**:23–7.
- Mitchell T, Lo A, Logan MR, et al. Primary granule exocytosis in human neutrophils is regulated by Rac-dependent actin remodelling. *Am J Physiol Cell Physiol* 2008;**295**:C1354–65.
- Tung JP, Fraser JF, Wood P, et al. Respiratory burst function of ovine neutrophils. *BMC Immunol* 2009;**10**:25.
- Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophils is mediated through activation of proteases by flux. *Nature* 2002;**416**:291–7.
- Rosenzweig SD. Inflammatory manifestations in chronic granulomatous disease. *J Clin Immunol* 2008;**28**:S67–72.
- Godoy MC, Vos PM, Cooperberg PL, et al. Chest radiographic and CT manifestations of chronic granulomatous disease in adults. *Am J Roentgenol* 2008;**191**:1570–5.
- King PT, Hutchinson P, Holmes PW, et al. Assessing immune function in adult bronchiectasis. *Clin Exp Immunol* 2006;**144**:440–6.
- Akira S, Hummi H. Recognition of pathogen associated molecular patterns by TLR family. *Immunol Lett* 2003;**85**:85–95.
- Droemann D, Goldmann T, Branscheid D, et al. Toll like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. *Histochem Cell Biol* 2003;**119**:103–8.
- Chaudhuri N, Dowse S, Whyte M, et al. Toll like receptors and chronic lung disease. *Clin Sci* 2005;**109**:125–33.
- Takeda K, Akira S. Roles of toll like receptors in innate immune responses. *Genes Cells* 2001;**6**:733–42.
- Netea M, van der Graaf C, Van der Meer JW, et al. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. *J Leukoc Biol* 2004;**75**:749–55.
- Review Toll-Like Receptors (TLRs) online. 2008. http://www.SABiosciences.com/pathway.php?sn=Toll_like_receptor (accessed Mar 2011).
- Akira S. Toll-like receptors: lessons from knockout mice. *Biochem Soc Trans* 2000;**28**:511–56.
- Martinez-Garcia MA, Soler-Cataluña JJ, Perpiñá-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. *Chest* 2007;**132**:1565–72.
- Evans SA, Turner SM, Bosch BJ, et al. Lung function in bronchiectasis: the influence of *Pseudomonas aeruginosa*. *Eur Respir J* 1996;**9**:1601–4.
- Ho PL, Chan KN, Ip MS, et al. The effect of *Pseudomonas aeruginosa* infection on clinical parameters in steady-state bronchiectasis. *Chest* 1998;**114**:1594–8.
- Skerrett SJ, Wilson CB, Liggett HD, et al. Redundant toll like receptor signalling in the pulmonary host response to *Pseudomonas aeruginosa*. *Am J Physiol Lung Cell Mol Physiol* 2007;**292**:L312–22.
- Adamo R, Sokol S, Soong G, et al. *Pseudomonas* flagella activate airway epithelial cells through toll like receptor 5. *Am J Respiratory Cell Mol Biol* 2004;**30**:627–34.
- Koller B, Kappler M, Latzin P, et al. The expression on neutrophils at the pulmonary site of infection: TLR1/TLR2-mediated up-regulation of TLR5 expression in cystic fibrosis lung disease. *J Immunol* 2008;**181**:2753–63.
- Wang X, Moser C, Louboutin JP, et al. Toll like receptor 4 mediates immune response to *Haemophilus influenzae* infection in the mouse lung. *J Immunol* 2002;**168**:810–15.
- Simpson JL, Grissell TV, Douwes J, et al. Innate immune activation in neutrophilic asthma and bronchiectasis. *Thorax* 2007;**62**:211–18.
- Tokairin Y, Shibata Y, Sata M, et al. Enhanced immediate inflammatory response to *Streptococcus pneumoniae* in the lungs of mice with pulmonary emphysema. *Respirology* 2008;**13**:324–32.
- Moore BB, Moore TA, Toews GB. Role of T and B lymphocytes in pulmonary host defence. *Eur Respir J* 2001;**18**:846–56.
- International Union of Immunological Societies. Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. *Clin Exp Immunol* 1999;**118**:S1–28.
- Kainulainen L, Varpula M, Liippo K, et al. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. *J Allergy Clin Immunol* 1999;**104**:1031–6.
- Quinti I, Soresina A, Spadaro G, et al. Long term follow up and outcome of a large cohort of patients with common variable immunodeficiency. *J Clin Immunol* 2007;**27**:308–16.
- Tarzi MD, Grigoriadou S, Carr SB, et al. Clinical immunology review series: an approach to the management of pulmonary disease in primary antibody deficiency. *Clin Exp Immunol* 2009;**155**:147–55.
- Chapel HM. Consensus on diagnosis and management of primary antibody deficiencies. Consensus panel for the diagnosis and management of primary antibody deficiencies. *BMJ* 1994;**308**:581–5.
- Buckley R. IgG subclass deficiency - IDF Clinical Focus on Primary Immune Deficiencies. 1998;1:1–4. <http://primaryimmune.org/publications?aid=409&pid=275&sa=1> (accessed Sep 2011).
- Hill SL, Mitchell JL, Burnett D, et al. IgG subclasses in the serum and sputum of patients with bronchiectasis. *Thorax* 1998;**53**:463–8.
- Stead A, Douglas JG, Broadfoot CJ, et al. Humoral immunity and bronchiectasis. *Clin Exp Immunol* 2002;**130**:325–30.
- Vendrell M, deGracia J, Rodrigo MJ, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown aetiology. *Chest* 2005;**127**:197–204.
- Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. *Clin Rev Allergy Immunology* 2000;**19**:183–204.

53. **Horn J**, Thon V, Bartonkova D, *et al*. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. *Clin Immunol* 2007;**122**:156–62.
54. **Waisbren BA**, Brown I. A factor in the serum of patients with persisting infection that inhibits the bactericidal activity of normal serum against the organism that is causing the infection. *J Immunol* 1966;**97**:431–7.
55. **Guttman RM**, Waisbren BA. Bacterial blocking activity of specific IgG in chronic pseudomonas infection. *Clin Exp Immunol* 1975;**19**:121–30.
56. **Hornick DB**, Fick RB. The immunoglobulin G subclass composition of immune complexes in cystic fibrosis—implications for the pathogenesis of the pseudomonas lung lesion. *J Clin Invest* 1990;**86**:1285–92.
57. **Thomassen MJ**, Demko CA. Serum bactericidal effect on *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *Infect Immun* 1981;**33**:512–18.
58. **MacLennan CA**, Gilchrist JJ, Gordon MA, *et al*. Dysregulated humoral immunity to nontyphoidal salmonella in HIV infected African adults. *Science* 2010;**328**:508–12.
59. **Asad S**, Opal S. Bench-to-bedside review: Quorum sensing and the role of cell to-cell communication during invasive bacterial infection. *Crit Care* 2008;**12**:236.
60. **Popat R**, Cruz SA, Diggle SP. The social behaviours of bacterial pathogens. *Br Med Bull* 2008;**87**:63–75.
61. **Bjarnsholt T**, Givskov M. The role of quorum sensing in the pathogenicity of the cunning aggressor *Pseudomonas aeruginosa*. *Anal Bioanal Chem* 2007;**387**:409–14.
62. **Telford G**, Wheeler D, Williams P. The *Pseudomonas aeruginosa* quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone has immunomodulatory activity. *Infect Immun* 1998;**66**:36–42.
63. **Ritchie AJ**, Jansson A, Stallberg J, *et al*. The *Pseudomonas aeruginosa* Quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone inhibits T-Cell differentiation and cytokine production by a mechanism involving an early step in T-Cell activation. *Infect Immun* 2005;**73**:1648–55.
64. **Smith RS**, Harris SG, Phipps R, *et al*. The *Pseudomonas aeruginosa* quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone contributes to virulence and induces inflammation in vivo. *J Bacteriol* 2002;**184**:1132–9.
65. **Tateda K**, Ishii Y, Horikawa M, *et al*. The *Pseudomonas aeruginosa* quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone accelerates apoptosis in macrophages and neutrophils. *Infect Immun* 2003;**71**:5785–93.
66. **Donlan R**, Costerton J. Biofilms: survival mechanisms of clinically relevant microorganisms. *Clin Microbiol Rev* 2002;**15**:167–93.
67. **deKievit TR**. Quorum sensing in *Pseudomonas aeruginosa* biofilms. *Environ Microbiol* 2009;**11**:279–88.
68. **Bryers JD**. Medical biofilms. *Biotechnol Bioeng* 2008;**100**:1–18.
69. **Parsek MR**. Biofilms 2003: emerging themes and challenges in studies of surface-associated microbial life. *J Bacteriol* 2004;**186**:4427–40.
70. **Patriquin GM**, Banin E, Gilmour C, *et al*. Influence of quorum sensing and iron twitching motility and Biofilm formation in *Pseudomonas aeruginosa*. *J. Bacteriol* 2008;**190**:662–71.
71. **Klausen M**, Heydorn A, Ragas P, *et al*. Biofilm formation by *Pseudomonas aeruginosa* wild type flagella and type IV pili mutants. *Mol Microbiol* 2003;**48**:1511–24.
72. **Davies DG**, Parsek MR, Pearson JP, *et al*. The involvement of cell to cell signals in the development of a bacterial biofilm. *Science* 1998;**280**:295–8.
73. **Shrout JD**, Chopp DL, Just CL, *et al*. The impact of quorum sensing and swarming motility on *Pseudomonas aeruginosa* biofilm formation is nutritionally conditional. *Mol Microbiol* 2006;**62**:1264–77.
74. **Walker TS**, Tomlin KL, Worthen GS, *et al*. Enhanced *Pseudomonas aeruginosa* biofilm development mediated by human neutrophils. *Infect Immun* 2005;**73**:3693–701.
75. **Winstanley C**, Fothergill JL. The role of quorum sensing in chronic cystic fibrosis *Pseudomonas aeruginosa* infections. *FEMS Microbiol Lett* 2009;**290**:1–9.